Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 2,465 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ovarian Tumors Clear all
Completed Early Phase 1 Interventional

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02316834
View directory record Official record
Conditions
Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Mass, Primary Peritoneal Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, BMN 673
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
6
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 30, 2026, 1:27 PM EDT
Recruiting Phase 2 Interventional

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT07285044
View directory record Official record
Conditions
Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma, Gastroesophageal Junction Carcinoma, Glioblastoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Hodgkin Lymphoma, Lung Carcinoma, Malignant Solid Neoplasm, Mantle Cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Multiple Myeloma, Myelodysplastic Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Primary Peritoneal Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
Cancer Therapeutic Procedure, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 1:27 PM EDT
Active, not recruiting Phase 1 Interventional

Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

NCT02637934
View directory record Official record
Conditions
Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Interventions
[18F]FluorThanatrace, PET/CT imaging sessions
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 3 Interventional

Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

NCT00004934
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
carboplatin, epirubicin hydrochloride, paclitaxel, conventional surgery
Drug · Procedure
Lead sponsor
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 30, 2026, 1:27 PM EDT
Not listed Phase 1Phase 2 Interventional

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

NCT00003064
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, carboplatin, etoposide phosphate, paclitaxel, thiotepa, topotecan hydrochloride, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

NCT01468909
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Paclitaxel, Pazopanib Hydrochloride, Placebo
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
142
States / cities
Mobile, Alabama • Phoenix, Arizona • Burbank, California + 106 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Not applicable Interventional

Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics

NCT02144311
View directory record Official record
Conditions
Ovarian Cancer
Interventions
PET/CT Scan, MRI
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 2 Interventional

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

NCT01033292
View directory record Official record
Conditions
Ovarian Cancer
Interventions
BSI-201
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 1 Interventional

UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors

NCT00047242
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
7-hydroxystaurosporine, irinotecan hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation

NCT01318005
View directory record Official record
Conditions
Oral Contraceptive
Interventions
Oral Contraceptive: Ortho-Novum® 1/35, Oral Contraceptive: Ovcon® 35, Oral Contraceptive: Microgestin Fe® 1/20
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 30, 2026, 1:27 PM EDT
Not listed Phase 1Phase 2 Interventional

Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer

NCT00553683
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
cyclophosphamide, poly ICLC, hepatic artery embolization, 3-dimensional conformal radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 30, 2026, 1:27 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients

NCT00418574
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Abagovomab, Placebo
Biological
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
22
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 30, 2026, 1:27 PM EDT
Terminated No phase listed Observational

Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00536523
View directory record Official record
Conditions
Constipation, Bowel Obstruction, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 1 Interventional

A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)

NCT05231746
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
hSTC810
Biological
Lead sponsor
STCube, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Results available

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

NCT00381888
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Thromboembolism, Vaginal Cancer, Vulvar Cancer
Interventions
fondaparinux sodium
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Minneapolis, Minnesota • Upland, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 30, 2026, 1:27 PM EDT
Active, not recruiting Not applicable Interventional

Myo-Inositol for Infertility in PCOS

NCT04407754
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Inositol supplement, Placebo supplement
Dietary Supplement
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 36 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 30, 2026, 1:27 PM EDT
Not yet recruiting Early Phase 1 Interventional

Lipid Mediators & Cancer: Montelukast, SPM, and Almonds

NCT06887673
View directory record Official record
Conditions
Colorectal Cancer, Sarcoma, Brain Tumors, Endometrial Cancer, Ovarian Cancer
Interventions
No Interventions, Sports Pro Resolve 4 g, Double Wood SPM 4 g, 20 California Sweet Almonds, Montelukast 10 Mg Oral Tablet, Montelukast 10 Mg Oral Tablet and SPM 4 g, Cold- Pressed Almond Oil 30 mL
Other · Dietary Supplement · Drug + 1 more
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 1 Interventional

Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors

NCT00028405
View directory record Official record
Conditions
Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma, Rectal Cancer, Breast Cancer, Colorectal Cancer, Mouth Cancer
Interventions
LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter
Drug · Device
Lead sponsor
Light Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
6
States / cities
Tucson, Arizona • Detroit, Michigan • Greenville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

NCT02101788
View directory record Official record
Conditions
Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
Interventions
Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tamoxifen Citrate, Topotecan, Trametinib Dimethyl Sulfoxide
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
488
States / cities
Huntsville, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 310 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 1 Interventional

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

NCT04881045
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
Interventions
PF-07257876
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 30, 2026, 1:27 PM EDT
Terminated Early Phase 1 Interventional Results available

Fermented Wheat Germ Extract in Women With Ovarian Cancer

NCT02411565
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Fermented Wheat Germ Extract (FWGE), Placebo, Standard of Care: Planned Surgery, Quality of Life (QoL) Surveys: FACT-O
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 30, 2026, 1:27 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

NCT03281681
View directory record Official record
Conditions
Ovarian Cancer
Interventions
VAL-083, Dianhydrogalactitol
Drug
Lead sponsor
DelMar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Phoenix, Arizona • Detroit, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 30, 2026, 1:27 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Data and Specimen Bank of Patients Diagnosed With, and at High-risk for, Gynecologic Cancers

NCT04170712
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Tampons
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 2 Interventional

Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy

NCT00006028
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cisplatin, gemcitabine hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
30
States / cities
Los Gatos, California • Tampa, Florida • Chicago, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 30, 2026, 1:27 PM EDT